Advanced neuroimaging protocol, including 3T MRI with triple-dose gadoteridol administration, for histopathological characterization of glioma and prediction of the patient's prognosis
Not Applicable
- Conditions
- Glioma
- Registration Number
- JPRN-UMIN000004846
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
(1)presence of contrast enhancement on T1-weighted 1.5 T MRI after intravenous administration of single-dose (0.2 ml/kg) gadoteridol; these patients will be enrolled into full investigational protocol but their data will be analyzed separately; (2)absence of surgical treatment in TWMU within 1 month after completion of the neuroradiological investigation; (3)establishment of any histpathological diagnosis after resective surgery other than glioma of astrocytic, oligodendroglial, or ependymal origin, neuronal or mixed neuronal-glial neoplasm.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method